Alto Neuroscience Financial Ratios
NYSE: ANROHealth CareBiotechnology: Pharmaceutical PreparationsUSD
24.37+0.34 (+1.41%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alto Neuroscience ratio analysis
Return on equity reached -41.8%, meaning Alto Neuroscience generated -0.42 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.11 versus 0.07 the year before, and the current ratio was 15.69. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Alto Neuroscience financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Price / book | 3.17 | 0.75 | — |
| Return on equity (ROE) | -41.8% | -40.6% | — |
| Return on assets (ROA) | -34.2% | -34.6% | -41.9% |
| Debt / equity | 0.11 | 0.07 | — |
| Current ratio | 15.69 | 16.92 | 15.22 |